VNRX (VolitionRX) Moat Score: 3/10 (As of Aug. 27, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VNRX VolitionRX Ltd VNRX
54 GF Score
Price $0.58
GF Value $17.52
Valuation Possible Value Trap
! 8 Warning Signs
View Full Analysis

What is VolitionRX Moat Score?

VolitionRX VNRX +71.31% 54 Moat Score is 3 as of Aug. 27, 2026. GuruFocus rates VNRX with a GF Score™ of 54/100 and a GF Value™ of $17.52 (Possible Value Trap). The stock has 8 warning signs investors should review. Among 835 Medical Devices & Instruments companies, VolitionRX ranks better than 75.57% on this metric.

VolitionRX has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

VolitionRX has No Moat: VolitionRX Ltd has weak competitive advantages. While it has some intellectual property in cancer diagnostics, it lacks market leadership, brand strength, and significant customer switching costs. The company's position is not yet durable enough to warrant a narrow moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes VolitionRX might have No Moat - Very weak/transient advantages.

VolitionRX  (AMEX:VNRX) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

VolitionRX Moat Score Related Terms

VNRX vs ALRTF, ADGM, NXL: Moat Score Comparison

For the Medical Devices subindustry, VolitionRX's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

VolitionRX Moat Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, VolitionRX's Moat Score distribution charts can be found below:

* The bar in red indicates where VolitionRX's Moat Score falls into.


VNRX
54GF Score
VolitionRX Ltd VNRX
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
VolitionRX (VNRX) has a Moat Score of 3 as of Aug. 27, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, VolitionRX ranks #204 out of 835 companies in the Medical Devices & Instruments industry, placing it in the top 24.4%.
Is VolitionRX's Moat Score too high?
VolitionRX's current Moat Score is 3. Based on the distribution chart, VolitionRX ranks #204 out of 835 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, VolitionRX has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does VolitionRX's Moat Score compare to ALRTF and ADGM?
According to the Medical Devices & Instruments industry distribution chart, VolitionRX ranks #204 out of 835 companies for Moat Score. This places VolitionRX in the top 24% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Devices & Instruments company?
A good Moat Score depends on the Medical Devices & Instruments industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. VolitionRX's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VolitionRX stock overvalued right now?
Based on GuruFocus' analysis, VolitionRX (VNRX) is currently considered Possible Value Trap. The stock's GF Value™ is $17.52, compared to a current price of $0.58 — trading 96.7% below its estimated fair value. The current Moat Score is 3. VolitionRX's overall GF Score™ is 54/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For VolitionRX (VNRX), the current Moat Score is 3 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is VolitionRX (VNRX) Overvalued in 2026?

Based on GuruFocus' analysis, VolitionRX stock appears to be undervalued. The current stock price of $0.58 is trading 96.7% below its estimated GF Value™ of $17.52. GuruFocus considers VolitionRX to be Possible Value Trap.

Key valuation signals for VNRX:

  • Moat Score: 3
  • GF Value™: $17.52 vs. price of $0.58 (96.7% below fair value)
  • GF Score™: 54/100 with 8 warning signs

No single metric tells the full story. See the VNRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

VolitionRX Business Description

Address 1489 West Warm Springs Road, Suite 110, Henderson, NV, USA, 89014
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on diagnostics and monitoring.
54GF Score

Get the complete analysis for VNRX

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.58
Price
$17.52
GF Value